Physician

Abdur R. Shakir, MD

According to 2025 Medicare claims, Abdur Shakir, MD (NPI: 1669583431) practices hematology/oncology, with the plurality of this provider's patient population coming from Coles, IL. This provider's primary affiliated billing organization is SARAH BUSH LINCOLN HEALTH CENTER (NPI: 1568581379; TIN: 237098532) and primary practice location at 61938-4693. Shakir is affiliated with the IRCCO (ACO ID: A2619) and SBL accountable care organization (ACO ID: A5147), participating under the MSSP model.

Shakir's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 378 traditional Medicare patients, billed 1,485 HCPCS/CPT codes, and received $79,250 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,392 prescription claims across 236 beneficiaries totaling $5,465,660 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 51 claims. Open Payments data shows 103 records totaling $10,076. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,085,214 to $5,465,660. For DME billing, reported payments moved sharply higher in recent years, from $2,042 to $123,084.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	365	1,379	$87,105
2016	406	1,510	$97,929
2017	427	1,546	$94,431
2018	466	1,842	$118,735
2019	479	1,905	$122,510
2020	538	2,269	$143,757
2021	492	1,886	$109,026
2022	448	1,417	$90,069
2023	386	1,176	$73,934
2024	378	1,485	$79,250

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	162	945	$1,085,214
2016	174	1,018	$1,471,055
2017	162	1,045	$1,671,634
2018	207	1,187	$1,970,605
2019	199	1,260	$2,332,688
2020	226	1,379	$2,913,435
2021	243	1,503	$3,636,259
2022	249	1,505	$4,066,993
2023	239	1,371	$4,157,831
2024	236	1,392	$5,465,660

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	104	$30,630
2016	N/R	39	$8,287
2017	N/R	181	$54,638
2018	N/R	102	$13,416
2019	N/R	13	$245
2020	N/R	93	$5,749
2021	N/R	131	$7,779
2022	N/R	45	$2,503
2023	N/R	57	$1,848
2024	N/R	51	$1,728

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	55	55	$143
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	227	640	$71
99442	Telephone medical discussion with physician, 11-20 minutes	59	94	$47
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	211	330	$47
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	217	338	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	54	1,620	$942,005
Imbruvica	Ibrutinib	38	1,090	$526,288
Fotivda	Tivozanib Hcl	15	420	$454,799
Verzenio	Abemaciclib	25	700	$349,298
Kisqali	Ribociclib Succinate	20	553	$333,963

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	15	$913
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	24	$589
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	103	$10,076	F. Hoffmann-La Roche AG
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Abdur R. Shakir, MD?

Tedicare shows public-source Medicare data for Abdur R. Shakir, MD (NPI 1669583431), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Abdur R. Shakir, MD have ACO affiliation data?

Abdur R. Shakir, MD is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619) and SBL accountable care organization (MSSP, ACO ID A5147).

What billing organization is linked to Abdur R. Shakir, MD?

Abdur R. Shakir, MD is linked to SARAH BUSH LINCOLN HEALTH CENTER (billing NPI 1568581379) in the available physician profile data.

Does Abdur R. Shakir, MD have Open Payments data?

Abdur R. Shakir, MD has 103 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.